Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
New and Future Focused Therapies for Thyroid Cancer
share announcement

New and Future Focused Therapies for Thyroid Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 15 February 2025 | Viewed by 723

Special Issue Editors

Prof. Dr. Alessandro Antonelli

E-Mail Website
Guest Editor
Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy
Interests: thyroid cancer; autoimmune thyroid diseases; thyroid irAE; Graves’ disease; thyroid eye disease; molecular basis of thyroid cancer; advanced thyroid cancer; tyrosine kinase inhibitors; medullary thyroid cancer; in vitro cell culture
Special Issues, Collections and Topics in MDPI journals
Dr. Poupak Fallahi

E-Mail Website
Guest Editor
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy
Interests: thyroid cancer; autoimmune thyroid diseases; thyroid irAE; Graves’ disease; thyroid eye disease; molecular basis of thyroid cancer; advanced thyroid cancer; tyrosine kinase inhibitors; medullary thyroid cancer; occupational health; public health, in vitro cell culture
Special Issues, Collections and Topics in MDPI journals
Dr. Silvia Martina Ferrari

E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Interests: chemokines; autoimmune thyroid disorders; thyroid cancer; primary cell cultures; autoimmunity
Special Issues, Collections and Topics in MDPI journals
Dr. Giusy Elia

E-Mail
Guest Editor
Department of Surgery, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy
Interests: thyroid cancer; immunotherapy; new checkpoint inhibitors; tyrosine kinase inhibitors; PD-1 inhibitors; PD-L1 inhibitors

Special Issue Information

Dear Colleagues,

The incidence of thyroid cancer (TC) is increasing worldwide and new strategy treatments are needed. Treatments against TC are based on the subtypes of TC; differentiated TC usually has a good prognosis, unlike dedifferentiated TC of which the prognosis is not so promising, and require a more challenging approach. Among the approved therapies for TC, for aggressive radioiodine-resistant papillary or follicular TC, multi-targeted kinase inhibitors sorafenib, lenvatinib and cabozantinib have been approved. New compounds acting against specific mutations such as dabrafenib and trametinib have been recently approved for the treatment of BRAFV600E-mutated anaplastic TC.

Lately, new advancements in the molecular field are permitting to choose appropriate and patient-tailored therapy for the treatment of thyroid cancer. 

Prof. Dr. Alessandro Antonelli
Dr. Poupak Fallahi
Dr. Silvia Martina Ferrari
Dr. Giusy Elia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • aggressive differentiated thyroid carcinoma
  • anaplastic thyroid cancer
  • tyrosine kinase inhibitors
  • immunotherapy
  • personalized medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 4490 KiB  
Article
The Potential Therapeutic Value of Aspirin in Anaplastic Thyroid Cancer
by Enke Baldini, Silvia Cardarelli, Eleonora Lori, Elena Bonati, Federica Gagliardi, Daniele Pironi, Poupak Fallahi, Alessandro Antonelli, Vito D’Andrea, Salvatore Ulisse and Salvatore Sorrenti
Cancers 2024, 16(24), 4203; https://doi.org/10.3390/cancers16244203 - 17 Dec 2024
Viewed by 412
Abstract
Background: several experimental findings and epidemiological observations indicated that aspirin/acetylsalicylic acid (ASA) may be endowed with anticancer effects against a variety of human malignancies, including thyroid carcinomas. Among these, undifferentiated/anaplastic thyroid carcinoma (ATC) is one of the most aggressive and lethal human cancers, [...] Read more.
Background: several experimental findings and epidemiological observations indicated that aspirin/acetylsalicylic acid (ASA) may be endowed with anticancer effects against a variety of human malignancies, including thyroid carcinomas. Among these, undifferentiated/anaplastic thyroid carcinoma (ATC) is one of the most aggressive and lethal human cancers, refractory to all currently available therapies. Methods: we here evaluated in a preclinical setting the effects of ASA on a panel of three ATC-derived cell lines: the CAL-62, the 8305C, and the 8505C. Results: the data obtained demonstrated the ability of ASA to inhibit, in a dose- and time-dependent manner, the proliferation of all ATC cell lines investigated, with IC50 values comprised between 2.0 and 4.3 mM. Cell growth was restrained with the same efficacy when the ASA treatment was applied to three-dimensional soft-agar cultures. In addition, ASA significantly reduced migration and invasion in two of the three ATC cell lines. We finally investigated the effects of ASA on the MAPK and PI3K/Akt signaling pathways, which are often altered in ATC. The results showed that the phosphorylation status of the Akt1/2/3 kinases was significantly reduced following ASA treatment, while ERK1/2 phosphorylation was either unaffected or slightly upregulated. Conclusions: our findings support epidemiological evidence on the anticancer potential of ASA. On this basis, further investigations should be carried out to assess the usefulness of ASA as adjuvant therapy in patients affected by ATC. Full article
(This article belongs to the Special Issue New and Future Focused Therapies for Thyroid Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop